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Abstract
Glucocorticoids are stress hormones that modulate a large number of physiological actions
involved in metabolic, inflammatory, cardiovascular and behavioral processes. The molecular
mechanisms and the physiological effects of glucocorticoids have been extensively studied.
However, the involvement of glucocorticoid action in the etiology of the Metabolic Syndrome has
not been well appreciated. Recently, accumulating clinical evidence and animal genetics studies have
attracted growing interest in the role of glucocorticoid action in obesity and insulin resistance. This
review will discuss the metabolic effects in the context of glucocorticoid metabolism and establish
the association of glucocorticoid action with the features of the Metabolic Syndrome, especially
obesity and insulin resistance. Special discussions will be focused on corticosteroid-binding globulin
and 11β-hydroxysteroid dehydrogenase type 1, two proteins that mediate glucocorticoid action
and have been implicated in the Metabolic Syndrome. Due to the complexities of the glucocorticoid
biology and the Metabolic Syndrome and limited space, this review is only intended to provide a
general link between the two areas with broad rather than in-depth discussions of clinical,
pharmacological and genetic findings.
Introduction
Insulin resistance and hyperinsulinemia are often associ-
ated with a group of risk factors such as obesity, dyslipi-
demia, hypertension and impaired glucose tolerance. This
cluster of metabolic abnormalities, first defined as Syn-
drome X by Reaven in 1988 [1] and supported by addi-
tional evidence [2,3], is now more often referred to as the
Metabolic Syndrome and has been increasingly recog-
nized as important risk factors for coronary artery disease
(CAD). The point of view became institutionalized and
although the National Cholesterol Education Program's
Adult treatment Panel III (ATP III) and the World Health
Organization (WHO) have slightly different definitions
[4-6], the Metabolic Syndrome is consistently character-
ized by a collection of metabolic abnormalities such as
insulin resistance, obesity, dyslipidemia, hyperglycemia,
and hypertension [7]. Not all of the disorders in the Met-
abolic Syndrome may be observed in the same individual.
Most people with the syndrome have insulin resistance
that could lead to glucose intolerance and diabetic hyper-
glycemia. Although the mechanisms underlying the
pathogenesis of the Metabolic Syndrome are not exactly
clear, obesity, insulin resistance and other independent
factors such as vascular and immunologic origins appear
to be involved [7]. The prevalence of the Metabolic Syn-
drome is more than 20% among the US adults adjusted
for age [8], which is far greater than observed in an earlier
study with European participants at least partly due to
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differences in the criteria used to define the condition [9].
Increased cardiovascular and mortality risks are associated
with the Metabolic Syndrome [10]. The condition is usu-
ally managed with pharmaceutical agents for correcting
dyslipidemia, anti-hypertensives, and insulin sensitizing
agents or a combination of the above. Most existing
agents only treat individual metabolic abnormalities. To
date, no single agent can ameliorate all the features of the
Metabolic Syndrome. There is an increasing need for
novel agents to treat multiple abnormalities of the
syndrome.
Glucocorticoid (GC) excess has been linked to clinical
observations associated with the Metabolic Syndrome. In
Cushing's syndrome [11], increased secretion of GCs
largely due to pituitary adenoma leads to central obesity,
hypertension, hyperlipidemia and glucose intolerance, a
group of metabolic abnormalities reminiscent of the Met-
abolic Syndrome. Correction of hypercortisolism by
transsphenoidal surgery at least normalizes blood pres-
sure [12,13]. In addition, clinical administration of GCs
to treat acute and chronic inflammatory diseases has been
associated with metabolic adverse effects such as hyper-
tension, obesity, hyperlipidemia and insulin resistance as
seen in the Metabolic Syndrome [14-16]. These clinical
findings suggest that GC action could play a role in the
pathophysiology of the Metabolic Syndrome.
GC metabolism and action
Cortisol, the principal active GC in humans, is secreted by
the adrenal gland and is converted to cortisone, the inert
GC, primarily in kidney [17-19]. Two isozymes of 11β-
hydroxysteroid dehydrogenase (11β-HSD) are responsi-
ble for the tissue-specific interconversion of cortisone and
cortisol at the endoplasmic reticulum: type 1 and 2 (11β-
HSD1 and 11β-HSD2) [20]. The two isozymes are prod-
ucts of two different genes and have distinct tissue distri-
butions, with 11β-HSD1 expressed primarily in liver,
adipose, kidney and brain and 11β-HSD2 mainly in kid-
ney and salivary glands [20]. 11β-HSD1 converts inactive
cortisone to cortisol in human or inactive 11-dehydrocor-
ticorsterone (11-DHC) to corticosterone in rodents and
11β-HSD2 catalyzes the opposite reaction. Bidirectional
activities (both reductase and dehydrogenase) have been
observed with 11β-HSD1 in vitro but it is mainly a reduct-
ase in vivo [21]. Since GC action is largely mediated by the
ligand-induced activation of the GC receptor (GR), the
local concentration of cortisol (or corticosterone) dictates
GR activation. In tissues such as liver and adipose where
11β-HSD1 is expressed, there are two sources for cortisol
(or corticosterone) accumulation: the fraction produced
by 11β-HSD1 within the tissue and that from the plasma
by diffusion. Obviously, 11β-HSD2 activity is responsible
for reducing the cortisol level in kidney [17-19]. In addi-
tion, cortisol metabolism in liver is part of the balance
maintaining the tissue-specific cortisol concentration.
The circulating cortisol level undergoes circadian varia-
tions peaking in the early morning at approximately 800
nM and reaching a nadir of about 200 nM at midnight
[22]. The plasma cortisone level is much lower and shows
no significant circadian rhythm [22]. The salivary cortisol
level exhibits a similar trend of diurnal rhythm [23].
Rodents housed under 12-h light, 12-h dark illumination
conditions exhibit an opposite pattern of circadian varia-
tion with lowest circulating corticosterone levels in the
early morning and the peak concentration at the light/
dark transition phase before declining to nadir [24]. The
plasma GC level is regulated by the activity of the hypoth-
alamic-pituitary-adrenal (HPA) axis, a neuroendocrine
feedback circuit that can be activated by physiological
stimuli such as stress [25]. Plasma cortisone is largely in
the free unbound form but approximately 6% cortisol is
bound to albumin and 90% is bound to corticosteroid-
binding globulin (CBG), a protein synthesized in liver
and secreted in blood [26,27]. Since only free cortisol is
active, CBG binding may restrict the access of cortisol to
target cells and regulate its bioavailability and metabolic
clearance. On the other hand, CBG may act as a carrier
protein for cortisol mediating its delivery to sites of
inflammation [28,29]. CBG is also present in several tis-
sues and may be involved in the regulation of tissue-spe-
cific GC action. For example, the significantly lower CBG
level in the adipose tissue of obese Zucker rats may con-
tribute to insulin resistance [30]. CBG levels are down reg-
ulated by physiological changes such as stress [31-33].
Both cortisol and cortisone are metabolized in liver first
by the A-ring reductases followed by several steps of fur-
ther structural transformation catalyzed by other enzymes
[20]. The final metabolites, 5α – and 5β-tetrahydrocorti-
sol (5α – and 5β-THF) and 5β-tetrahydrocortisone (THE),
are eliminated through urinary excretion and are often
used as biomarkers for GC metabolism [20,34]. While the
total urinary tetrahydro metabolites (THF and THE) may
serve as an indicator for GC metabolism or activity, using
the ratio of the urinary THF to THE to predict the intercon-
version of cortisol and cortisone by 11β-HSDs is question-
able for the following reasons: First, the ratio is a
reflection of the total metabolism of cortisol and corti-
sone in the whole body instead of one particular tissue
because the two isozymes have distinct tissue distribution
patterns. Second, other enzymes, including the A-ring
reductases and those involved in the subsequent meta-
bolic steps forming THF and THE, also contribute to the
balance between cortisol and cortisone. Therefore, the uri-
nary ratio of THF to THE is determined by the combined
activities of different enzymes in multiple tissues. AnotherNutrition & Metabolism 2005, 2:3 http://www.nutritionandmetabolism.com/content/2/1/3
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convenient way to measure GC metabolism is to measure
the salivary cortisol levels [20].
GC action is mediated by GR, a nuclear receptor that reg-
ulates physiological events through activation or repres-
sion of target genes involved in inflammation,
gluconeogenesis and adipocyte differentiation [35,36].
Upon activation, a GR dimer binds to GC response ele-
ments (GREs), interacts with components of the transcrip-
tion machinery and activates the transcription of
downstream genes [35,36]. The ligand-bound GR could
also bind to negative GREs (nGREs) that mediate the
repression of gene transcription, or the starting point of
transcription and thus interferes with the general tran-
scription machinery [35,36]. Some transrepression effects
of GC action are achieved through a DNA binding-inde-
pendent process, in which GR interacts with transcription
factors such as AP-1 and NFκB and represses their activity
on gene expression [37-39]. Repression of NFκB mediated
transcription by GC can also be achieved by induction of
IκB synthesis [40,41]. Examples of genes regulated by GR
and involved in the hepatic gluconeogenesis, adipocyte
differentiation, hormonal control, and inflammation are
summarized in Table 1[39,42-66]. The gene stimulation
or suppression effects mediated by activated GR sequen-
tially regulate a myriad of physiological actions in
response to GCs. Since the pool of active cortisol or corti-
costerone is the active ligand for GR, the availability of
free cortisol or corticosterone mediated largely by CBG-
dependent protein binding and tissue-specific activities of
11β-HSDs are critical for GC action. The role of GC action
in obesity and insulin resistance is implicated by the bio-
logical or physiological consequences of deficiency or
activation of CBG or 11β-HSDs (see below). The GC pro-
duction and tissue-specific conversions are illustrated in
Figure 1.
Clinical association of GC action and the 
Metabolic Syndrome
Accumulating clinical evidence has demonstrated the
association of abnormal GC metabolism and the Meta-
bolic Syndrome. The plasma cortisol levels were increased
in an elderly cohort with one or more features of the Met-
abolic Syndrome [67]. Further, a good correlation was
Table 1: Examples of genes regulated by GR
Gene Names Function Regulation Reference
Glutamine synthetase Amino acid metabolism Up 42
TAT Amino acid catabolism Up 43, 44
Tryptophan oxygenase Amino acid catabolism Up 45
PEPCK (liver) Gluconeogenesis Up 46
G6Pase Gluconeogenesis Up 47, 48
Angiotensinogen Precursor of angiotensin I; vasoconstriction, electrolyte balance, etc. Up 49
Leptin Energy metabolism Up 50
VLDLR Lipoprotein metabolism Up 51
PEPCK (adipose) Glyceroneogenesis Down 52
aP2 Intracellular lipid shuttling and metabolism Up 53
GLUT4 Glucose transport Up 53
HSL Lipolysis Up 53
LPL Lipid metabolism Up 53
TNF-α Inflammation and apoptosis Down 53
Osteocalcin Marker for mature osteoblasts Down 54, 55
CRH Stress mediated/feedback hormone release Down 56
POMC Precursor of pituitary hormones Down 57, 58
Prolactin Hormone critical for reproduction Down 59
Proliferin Angiogenesis Down 60, 61
Glycoprotein hormone α-subunit Common subunit of gonadotropin hormones Down 62, 63
IL-6 Proinflammatory cytokine Down 64
IL-8 Proinflammatory cytokine Down 65
Collagenase Matrix protease Down 66
ICAM-1 Inflammatory response Down 39
Abbreviations: TAT, tyrosine aminotransferase; PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose-6-phosphatase; VLDLR, very low 
density lipoprotein receptor; aP2, adipocyte fatty acid binding protein or A-FABP; GLUT-4, glucose transporter 4; HSL, hormone sensitive lipase; 
LPL, lipoprotein lipase; TNF-α, tumor necrosis factor α; CRH, corticotrophin-releasing hormone; POMC, proopiomelanocortin; IL-6, interleukin 6; 
IL-8, interleukin 8; ICAM-1, intercellular adhesion molecule 1.Nutrition & Metabolism 2005, 2:3 http://www.nutritionandmetabolism.com/content/2/1/3
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observed between total urinary GC metabolites and the
number of features of the Metabolic Syndrome in these
patients [67]. Both the secretion rate and peripheral clear-
ance of cortisol in these patients were positively correlated
with systolic blood pressure, fasting glucose and insulin
[67]. In agreement with this finding, stress-related cortisol
secretion in a population of 51-yr-old men showed asso-
ciations with diastolic blood pressure, fasting glucose and
insulin [68]. Several additional reports also suggest corre-
lation of increased GC activity with insulin resistance,
hyperglycemia and hypertension [69-71]. Although one
study indicated that plasma cortisol levels decreased in
obese women due to increased metabolic clearance [72],
stress-induced cortisol response is consistently correlated
with obesity in independent studies suggesting increased
HPA activity in obesity [73-77]. Higher adrenocortical
activity was also observed in children with higher body fat
mass [78,79]. Weight loss led to lower plasma cortisol and
reduced insulin resistance [79]. A study in the general
population indicates that even modestly increased corti-
sol levels contribute to obesity [80], and insulin resistance
is positively associated with cortical activity [81,82]. These
clinical findings demonstrate the strong correlation of
Glucocorticoid metabolism Figure 1
Glucocorticoid metabolism. The secretion of glucocorticoids by the adrenal gland is regulated by the HPA axis via secretion of 
ACTH. The main plasma cortisol (F) is protein bound with 4–5% free fraction. The plasma cortisone (E) is in the free unbound 
form. The equilibrium of cortisol and cortisone between the plasma and tissues are illustrated with the dotted bidirectional 
arrows. Tissue-specific GC metabolism are also depicted. GCs are metabolized primarily in liver and the metabolites are 
excreted in the urine. Only tissues relevant to the Metabolic Syndrome are shown. THE, tetrahydrocortisone; THF, 
tetrahydrocortisol.
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increased GC activity with the features of the Metabolic
Syndrome in humans.
The metabolic effects of GCs
The clinical correlation studies raised the possibility that
GC action could play a role in the origin of the features of
the Metabolic Syndrome. This notion was further estab-
lished and supported by animal studies to address the
metabolic effects of GCs. Adrenalectomy in young ob/ob or
db/db  mice slowed body weight gain [83]. Upon GC
administration, these animals retained body weight gain
with concomitant increase in food intake [83]. Likewise,
obese Zucker rats lost body fat mass after adrenalectomy
and remained so even after exogenous administration of
low doses of GCs [84]. The adrenalectomy resulted in sig-
nificantly reduced plasma insulin, glucose and triglyceride
levels [84]. As the doses of administered GCs increased,
the plasma insulin and triglyceride levels were elevated
[84]. Similar results were observed in another study using
adrenalectomized rats with diet-induced obesity demon-
strating the effects of GC action on plasma and liver trig-
lyceride levels, plasma insulin, and adipose tissue weight
[85]. These effects appear to be minimized when there is
restriction on high-energy diet [86], suggesting they may
be exerted via mediating the central ingestive behavior.
These findings highlight the central role of GCs in the
development of obesity and other features of the Meta-
bolic Syndrome.
The metabolic effects of GCs are mediated by several
mechanisms that are physiologically relevant to hepatic
and peripheral insulin resistance, dyslipidemia, obesity
and hyperglycemia. Events driven by these mechanisms
take place across the tissues contributing to the abnormal-
ities in the Metabolic Syndrome (Fig. 2). In liver, GCs
increase the activities of enzymes involved in fatty acid
synthesis and promote the secretion of lipoproteins
[87,88]. The hepatic lipogenic effect of GCs is consistent
with clinical findings that GC therapy causes triglyceride
accumulation within the liver [89-91]. Since liver fat
appears to be involved in the negative regulation of
hepatic insulin sensitivity [92] and is associated with cer-
tain features of the Metabolic Syndrome independent of
visceral fat mass [93-96], hepatic fat accumulation pro-
moted by GCs is likely to contribute to the pathophysiol-
ogy of the Metabolic Syndrome. GCs also induce the
hepatic gluconeogenic pathway via the activation of GR,
which stimulates the expression of phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase
(G6Pase), the rate-limiting enzymes in gluconeogenesis
[97,98]. This results in increased hepatic glucose output
and hyperglycemia. In adipose tissue, GCs promote the
differentiation of pre-adipocytes to adipocytes, which
could lead to increased body fat mass [99,100]. However,
once differentiated, the adipocytes develop insulin resist-
ance in the presence of GCs with decreased insulin-stimu-
lated glucose uptake without changing their ability to
bind insulin [101]. The reduced insulin sensitivity appears
to be mediated by GC antagonizing the insulin-stimu-
lated translocation of glucose transporters from intracel-
lular compartments to the plasma membrane [102-104].
A similar mechanism is likely responsible for the GC-
induced insulin resistance in skeletal muscle [105]. GCs
also inhibit insulin-stimulated amino acid uptake by adi-
pocytes [106]. Increased lipolysis or lipid oxidation could
be also involved in the peripheral insulin resistance
induced by GCs [107,108]. GCs inhibit insulin secretion
by the pancreatic β cells in animals and perturb high-fre-
quency insulin release in the fasting state in human
[109,110]. GC action has been implicated in hyperten-
sion as well. GCs are agonists of mineralocorticoid recep-
tor (MR), which upon activation leads to renal salt
retention and elevated blood pressure. The expression of
both 11β-HSD1 and 11β-HSD2 in kidney suggests the
interconversion of inert and active GCs is maintained in a
balance so that MR activation can be controlled tissue-
specifically [111]. GC excess as a result of either increased
11β-HSD1 activity or reduced 11β-HSD2 activity leads to
MR activation and hypertension. GCs also increase aortic
vasoconstriction through unknown mechanisms. The
expression of 11β-HSD1 in aortic endothelial cells is con-
sistent with such a notion and suggests this could be a sec-
ond pathway for GC induced hypertension [112-114].
These data, both physiologically and mechanistically, sug-
gest that the metabolic effects of GCs are exerted in multi-
ple tissues and increased GC action contributes to the
etiology of the Metabolic Syndrome. Through molecular
and genetic studies, more information has become avail-
able to dissect the role of tissue-specific GC action in the
features of the Metabolic Syndrome. Genetic studies with
the main players in GC action have been most revealing.
Since GR has been well reviewed in other publications,
this review will only discuss CBG and 11β-HSD1.
Modulation of GC action by CBG is associated 
with adiposity
CBG is not only in the blood but also found in tissues
[115,116]. Since CBG is the main GC binding protein, its
tissue distribution and local levels play important roles in
GC action. Intuitively, CBG level should be negatively cor-
related with the free cortisol or corticosterone
concentration because of its role in restricting free GC
fraction. This is especially true in a tissue-specific manner.
For example, the reduced adipose CBG level in obese
Zucker rat results in elevated free local corticosterone that
may have contributed to the obesity and insulin resistance
phenotype [30]. In general, in the human population,
serum CBG levels are negatively correlated with a variety
of parameters important in defining the Metabolic Syn-Nutrition & Metabolism 2005, 2:3 http://www.nutritionandmetabolism.com/content/2/1/3
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drome: body mass index (BMI), waist to hip ratio (WHR),
blood pressure and HOMA [117]. However, over-expres-
sion or secretion of CBG in the liver could lead to com-
pensatory activation of the HPA axis and consequently
elevated adrenal production of cortisol or corticosterone.
This feedback response leads to a global effect of elevated
total and free cortisol or corticosterone levels. This was
observed in a pig genetic model with high fat deposits and
low muscle content, where the hepatic CBG expression
was significantly higher than in another population and
the total and free cortisol levels were elevated [118]. On
the other hand, drastic reduction of CBG concentration or
its capacity to bind cortisol or corticosterone can also
cause compensatory response by the HPA axis. A familial
CBG deficiency led to decreased total and free plasma cor-
tisol levels and hypotension [119]. Likewise, a human
CBG polymorphism associated with reduced affinity for
cortisol only led to a marginal increase in serum free cor-
tisol, possibly due to the negative regulation of cortisol
production by the HPA axis [120]. Together, these data
demonstrate the importance of CBG level and its cortisol
binding capacity in modulating GC action and origina-
tion of the Metabolic Syndrome. Further, these studies
also suggest that the variation in CBG level or capacity
may trigger compensatory response of the HPA axis to bal-
ance plasma free cortisol concentrations.
Despite the compensatory response by the HPA axis to
balance the plasma free cortisol or corticosterone concen-
trations under conditions of CBG reduction or deficiency,
The link between the metabolic effects of glucocorticoids and the features of the Metabolic Syndrome Figure 2
The link between the metabolic effects of glucocorticoids and the features of the Metabolic Syndrome. The major effects in dif-
ferent tissues are summarized and the potential physiological links to the Metabolic Syndrome are shown.
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tissue-specific GC excess can still occur. This is especially
important with respect to GC-stimulated differentiation
of pre-adipocytes and insulin resistance of mature adi-
pocytes, with the former effect increasing fat content and
the latter reducing the tissue sensitivity to insulin. For
instance, preadipocytes from an individual with CBG
deficiency had increased proliferation and enhanced dif-
ferentiation compared to normal cells [121], which may
be responsible for the increased adiposity in CBG defi-
ciency. This notion was observed in genetic models of
obesity and insulin resistance. The CBG capacity the white
adipose tissue of Zucker rat is lower than that in its lean
counterpart [30,122], suggesting increased GC action in
the obese adipose tissue that could contribute to the obese
and insulin resistance phenotype.
11β-HSD1 and obesity and insulin resistance
Both 11β-HSD1 and 11β-HSD2 are located at the endo-
plasmic reticulum (ER) but with distinct topologies. 11β-
HSD1 has one short N-terminal transmembrane region
with the catalytic domain protruding into the ER lumen;
in contrast, the N-terminus of 11β-HSD2 is lumenal with
the catalytic domain facing the cytoplasm [123-125]. The
primary role of 11β-HSD2 is to prevent renal GC excess
and consequent MR activation by inactivating cortisol or
corticosterone, as mice deficient in 11β-HSD2 had
hypokalemia and hypertension [126]. Given the growing
interest in 11β-HSD1 and its role in the Metabolic Syn-
drome, this section will primarily focus on this isozyme.
Dysregulation of tissue-specific 11β-HSD1 expression and
activity has been observed in obese diabetic animal mod-
els and humans. Compared with their lean littermates, ob/
ob  mice have reduced hepatic 11β-HSD1 activity but
higher corticosterone level in liver due to their elevated
plasma corticosterone [127]. As a result, the liver PEPCK
expression is elevated at least partly contributing to hyper-
glycemia. However, the hepatic 11β-HSD1 activity is mar-
ginally increased in db/db mice [128]. As in ob/ob mice, the
11β-HSD1 activity is decreased in liver but increased in
omental fat in obese Zucker rats [129,130]. Although
both impaired hepatic regeneration of cortisol by 11β-
HSD1 and elevated adipose 11β-HSD1 activity were
observed in obese humans [131,132], the association of
adipose 11β-HSD1 activity with obesity, insulin resistance
and other features of the Metabolic Syndrome has been
consistently observed in different groups of obese sub-
jects, including obese men and women [131,133,134].
However, no difference in 11β-HSD1 activity was detected
between obese type 2 diabetics and their obese controls,
suggesting the dysregulation of 11β-HSD1 is better associ-
ated with obesity than the diabetic phenotype [135]. In-
situ hybridization revealed that 11β-HSD1 mRNA is
increased in both subcutaneous and visceral fat in obese
subjects [136]. The association of adipose 11β-HSD1 with
BMI and other features of the Metabolic Syndrome was
also found in populations of different ethnic backgrounds
[137]. In a group of young adult monozygotic twins, the
intrapair differences in BMI are positively correlated with
those in adipose 11β-HSD1 expression [138]. This associ-
ation is clearly established on the same genetic back-
ground, confirming the direct link of adipose 11β-HSD1
activity and adiposity. Most of these association studies
were done with subcutaneous fat. It is important to note
that 11β-HSD1 activity is higher in omental fat and sub-
ject to stimulation [139]. The activity of 11β-HSD1 in adi-
pocytes is relevant for the correlation since the activity in
cultured preadipocytes does not appear to be correlated
with obesity [140]. These association studies suggest that
the adipose 11β-HSD1 may be a contributing factor to
obesity and insulin resistance. In agreement with this con-
clusion, treatment of obese Zucker rats with carbenox-
olone slightly improved lipid profile but had no effect on
obesity and insulin resistance, because only the hepatic
11β-HSD1 but not that in adipose tissue was inhibited
[141]. It is important to note that carbenoxolone also
inhibits 11β-HSD2 and further studies with selective 11β-
HSD1 inhibitors are needed to confirm this observation.
In contrast to increased adiposity in the Metabolic Syn-
drome, some human immunodeficiency virus (HIV)-
infected patients treated with combined highly active
antiretroviral therapy (HAART) develop a lipodystrophic
syndrome. The condition is characterized with loss of sub-
cutaneous fat, accumulation of abdominal fat, hypertrig-
lyceridemia and insulin resistance [142]. The condition is
also referred to as pseudo-Cushing's syndrome because
the distribution of fat accumulation in these patients is
similar to that in Cushing's syndrome but their circulating
cortisol levels are not elevated [143]. Interestingly,
patients with lipodystrophy were shown to have higher
levels of subcutaneous adipose 11β-HSD1 expression and
higher ratios of urinary cortisol:cortisone metabolites
than non-lipodystrophic patients [144]. These findings
suggest that 11β-HSD1 could play a role in mediating the
metabolic abnormalities of the HAART-associated lipod-
ystrophy with the almost complete loss of subcutaneous
fat. This further suggests that the expression of 11β-HSD1
seems to be more important to the metabolic state than
the amount of subcutaneous fat though further investiga-
tion is required.
Genetic studies using animal models support the findings
in the clinical studies. In mice deficient in 11β-HSD1 gen-
erated through targeted gene disruption, there was no
conversion of the inert 11-dehydrocorticosterone to corti-
costerone and attenuation of the hepatic activities of
PEPCK and G6Pase, two key gluconeogenic enzymes
[145]. These mice consumed more calories but were resist-
ant to high fat diet-induced obesity, insulin resistance and
hyperglycemia with improved lipoprotein profile [145-Nutrition & Metabolism 2005, 2:3 http://www.nutritionandmetabolism.com/content/2/1/3
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147]. Concomitant with these phenotypes, the adipose
expression of TNF-α decreased, and adiponectin, PPARγ,
and UCP-2 increased indicating insulin sensitization
[146]. There were no bone marrow adipocytes in these
knockout animals but bone formation appeared to be
normal, suggesting that intracellular GC action may not
play a role in bone formation [148]. The HPA axis appears
to be activated in the 11β-HSD1 knockout mice. There
was compensatory adrenal hyperplasia, increased secre-
tion of corticosterone and exaggerated ACTH and corti-
costerone response to stress [145,149]. The plasma CBG
levels were slightly reduced [149]. These findings with
11β-HSD1 deficiency suggest inhibition of this enzyme
could help ameliorate some of the features of the Meta-
bolic Syndrome. However, compensatory response from
the HPA axis and the induced adrenal activity can occur.
Interestingly, 11β-HSD1 knockout ameliorated age-
related learning impairments but the underlying mecha-
nism is not clear [150]. The importance of 11β-HSD1 in
the Metabolic Syndrome was also demonstrated with 11β-
HSD1 transgenic animals. Mice with adipose-specific
overexpression of the rat 11β-HSD1 had increased adi-
pose levels of corticosterone and acquired features of the
Metabolic Syndrome: diet-induced visceral obesity, insu-
lin resistance, hyperlipidemia and hyperphagia [151]. The
transgenic mice also developed hypertension, at least in
part due to the increased adipose expression of angi-
otensinogen and the consequent activation of the rennin-
angiotensin system (RAS) [152]. In contrast, selective
overexpression of 11β-HSD1 in liver only caused mild
insulin resistance with no effect on fat depot mass [153],
although impaired hepatic lipid clearance and hyperten-
sion were observed in these animals. These transgenic
studies demonstrate that both the hepatic and adipose
11β-HSD1 activities contribute in some way to insulin
resistance and other features of the Metabolic Syndrome.
However, the adipose activity appears to be correlated
with a stronger phenotype of obesity and insulin resist-
ance and therefore is likely the primary target for the treat-
ment of insulin resistance. The hepatic 11β-HSD1 activity,
although secondary, appears to be more important in
improving lipid metabolism and controlling blood pres-
sure. Several cases of human 11β-HSD1 deficiency have
been reported. The ability of these subjects to convert cor-
tisone to cortisol upon dexamethasone suppression was
apparently compromised [154-158]. These patients
appeared to be normal except for mild adrenal hyperpla-
sia in some cases, and hirsutism, and elevated plasma cor-
tisol levels [154-158]. Unfortunately, insufficient insulin
sensitivity data have been reported with these patients.
Although both obese and lean patients with 11β-HSD1
deficiency have been identified, it is not clear if the body
weight is associated with 11β-HSD1 deficiency. However,
polymorphisms in the 11β-HSD1 gene have been linked
to adiposity in association studies with human subjects
[159,160].
Inhibitors of GC action
Given its important role in the Metabolic Syndrome,
antagonizing GC action has been taken as an approach to
treat some features of the Metabolic Syndrome. Targeting
GR is a direct approach to antagonize the GC action. The
global effect on GC action by this approach could lead to
the activation of the HPA axis as well as blocking the anti-
inflammatory function of GCs. Inhibition of 11β-HSD1
activity offers more tissue specificity due to the limited
expression pattern of this enzyme. Inhibitors for both
11β-HSD1 and GR include naturally occurring and phar-
maceutically developed compounds.
The expected effects of 11β-HSD1 inhibition include
reduced hepatic PEPCK and G6Pase expression to reduce
hepatic glucose output; reduced adiposity and improved
peripheral insulin sensitivity. Since 11β-HSD1 mediated
GC action inhibits glucose-dependent insulin secretion
[161] and the expression of 11β-HSD1 is significantly
increased in diabetic islets [162], 11β-HSD1 inhibitors
can potentially help reduce postprandial glucose excur-
sion. Several inhibitors of 11β-HSD1 were described in
the literature prior to the pharmaceutical targeting of this
enzyme in recent years but none of them is selective and
highly potent. Metyrapone, often used in the diagnosis of
adrenal corticoid-related disease such as Cushing' syn-
drome, is a weak competitive inhibitor of 11β-HSD1
[163]. Other inhibitors include liquorice derivatives
carbenoxolone (CBX) and glycyrrhetinic acid (GE) [164].
GE is more potent against the dehydrogenase activity and
CBX is almost equally potent against activities of both
directions (dehydrogenase and reductase). Although far
more potent than other inhibitors, CBX and GE are not
selective because they also inhibit 11β-HSD2. Chenode-
oxycholic acid (CDCA) inhibits 11β-HSD1 with a potency
of micromolar range but studies of its activity against 11β-
HSD2 have generated conflicting results [165-167].
Although not selective, CBX has been used in human
studies where it reduced glucose production during hyper-
glucagonemia largely due to its suppressive effect on gly-
cogenolysis in lean male patients with type 2 diabetes
[168]. Interestingly, CBX also improved verbal frequency
and memory in healthy elderly men and patients with
type 2 diabetes [169]. This is consistent with findings in
11β-HSD1 knockout mice [150]. Selective 11β-HSD1
inhibitors have been developed for pharmaceutical use in
recent years. These inhibitors have been shown to be effi-
cacious in diabetic animal models [170-173].
GR antagonists were developed on the rationale that acti-
vated GR stimulates PEPCK and G6Pase, the two key
enzymes in hepatic gluconeogenesis that increases theNutrition & Metabolism 2005, 2:3 http://www.nutritionandmetabolism.com/content/2/1/3
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hepatic glucose output [97,98,174]. Since hepatic gluco-
neogenesis in diabetics is increased [175], inhibition of
hepatic GR action is expected for glucose lowering in dia-
betics. A well-known GR antagonist is RU-486, which was
also found to have agonist activities [176]. Although effi-
cacious [177], long-term systemic treatment with a GR
antagonist may activate the HPA axis and increases
cortisol secretion [178]. Other GR antagonists were also
reported but without resolving the issue of HPA activation
[179]. Selective inhibition of the hepatic GR activation in
a non-systemic manner could provide advantages with no
undesirable side effects. Liver selective targeting of the
drug appears to be a good strategy [180].
Conclusions
GCs are stress hormones with a wide spectrum of physio-
logical effects and have been implicated in the pathophys-
iology of the Metabolic Syndrome. This notion has been
supported by animal studies and clinical findings. The GC
action appears to mediate certain aspects of the Metabolic
Syndrome. In that regard, targeting key players in the GC
action is expected to be a viable approach to treat some or
all the features of the Metabolic Syndrome. However, cau-
tions should be taken because the GC metabolism is reg-
ulated by the HPA axis and inhibition of GC pathways
could lead to the activation of HPA axis and elevated adre-
nal cortisol secretion. To avoid the compensatory feed-
back response, efforts to separate the effect of GC
modulators from HPA activity is needed. Although chal-
lenging, this could be achieved by tissue-specific modula-
tion of GC action by targeting drugs to tissues of interest
while sparing others, especially the CNS where HPA acti-
vation occurs. The availability of small molecule com-
pounds will facilitate this type of studies in animal
models to further dissect the regulatory function of the
HPA axis and help assess whether tissue selective modula-
tion of GC action without triggering the HPA axis is
achievable.
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